SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Costantino who wrote (569)10/1/1996 4:40:00 PM
From: Richard Mazzarella   of 4342
 
Rick, this is the item I saw on the PRLN webpage: <<Further trials at the Frederick Research Center show that PN355 increased the efficacy of Glaxo Welcome's AZT in the inhibition of replication of the AIDS virus. In addition, Paracelsian's product PN27,1 has demonstrated the effective inhibition of cancer and restenosis (an adverse response to angioplasty occurring in 40-50 percent of patients within several months of the procedure).>> I had not seen the Glaxo comment before, have you? I could see a dietary supplement product to improve the response for AZT. What do you think?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News